Metformin: An anti-diabetic drug to fight cancer

Pharmacological Research

Volumn 113, Issue , 2016, Pages 675-685

  Daugan, Marie ^a   Dufaÿ Wojcicki, Amélie ^a   d'Hayer, Benoit ^a,b   Boudy, Vincent ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b Centre National de la Recherche Scientifique   (France)

Author keywords

AMPK pathway; Biomarkers; Cancer; CSCs; Cytotoxic; Metformin

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DNA; DOXORUBICIN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; OCTAMER TRANSCRIPTION FACTOR 1; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; PROTEIN KINASE LKB1; ANTIDIABETIC AGENT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL CYCLE; CHEMOPROPHYLAXIS; COLON CANCER; CYTOSTASIS; DIABETES MELLITUS; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SELECTIVITY; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSARCOMA; GENE; GENE MUTATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INSULINEMIA; LIPID METABOLISM; LKB1 GENE; LUNG CANCER; MONOTHERAPY; OCT1 GENE; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN METABOLISM; RADIOSENSITIZATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; CELL PROLIFERATION; DRUG EFFECTS; METABOLISM; NEOPLASM;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84991769403     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.10.006     Document Type: Review

References (141)

1. [1] Witters, L.A., The blooming of the French lilac. J. Clin. Invest. 108:October (8) (2001), 1105–1107.
2. [2] Dowling, R.J., Goodwin, P.J., Stambolic, V., Understanding the benefit of metformin use in cancer treatment. BMC Med., 9(April (1)), 2011, 33.
3. [3] Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., Bost, F., Metformin in cancer therapy: a new perspective for an old antidiabetic drug?. Mol. Cancer Ther. 9:May (5) (2010), 1092–1099.
4. [4] Schäfer, G., Biguanides. A review of history, pharmacodynamics and therapy. Diabete Metab. 9:June (2) (1983), 148–163.
5. [5] Foretz, M., Guigas, B., Bertrand, L., Pollak, M., Viollet, B., Metformin: from mechanisms of action to therapies. Cell Metab. 20:December (6) (2014), 953–966.
6. [6] Forouzandeh, F., Salazar, G., Patrushev, N., Xiong, S., Hilenski, L., Fei, B., Alexander, R.W., Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis. J. Am. Heart Assoc., 3(December (6)), 2014, e001202.
7. [7] Kinaan, M., Ding, H., Triggle, C.R., Metformin: an old drug for the treatment of diabetes but a new drug for the protection of the endothelium. Med. Princ. Pract.(May), 2015.
8. [8] Hattori, Y., Hattori, K., Hayashi, T., Pleiotropic benefits of metformin: macrophage targeting its anti-inflammatory mechanisms. Diabetes 64:June (6) (2015), 1907–1909.
9. [9] Khang, R., Park, C., Shin, J.-H., Dysregulation of parkin in the substantia nigra of db/db and high-fat diet mice. Neuroscience 294:May (2015), 182–192.
10. [10] Quinn, B.J., Kitagawa, H., Memmott, R.M., Gills, J.J., Dennis, P.A., Repositioning metformin for cancer prevention and treatment. Trends Endocrinol. Metab. 24:September (9) (2013), 469–480.
11. [11] Foretz, M., Viollet, B., New promises for metformin: advances in the understanding of its mechanisms of action. Med. Sci. (Paris) 30:January (1) (2014), 82–92.
12. [12] Krishan, S., Richardson, D.R., Sahni, S., Adenosine monophosphate-activated kinase and its key role in catabolism: structure, regulation, biological activity, and pharmacological activation. Mol. Pharmacol. 87:3 (2015), 363–377.
13. [13] Meng, S., Cao, J., He, Q., Xiong, L., Chang, E., Radovick, S., Wondisford, F.E., He, L., Metformin activates AMP-activated protein kinase by promoting formation of the αβγ heterotrimeric complex. J. Biol. Chem.(December), 2014 p. jbc.M114.604421.
14. [14] Russo, G.L., Russo, M., Ungaro, P., AMP-activated protein kinase: a target for old drugs against diabetes and cancer. Biochem. Pharmacol. 86:August (3) (2013), 339–350.
15. [15] Faubert, B., Vincent, E.E., Poffenberger, M.C., Jones, R.G., The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator. Cancer Lett. 356:January (2) (2015), 165–170 (Part A).
16. [16] Hardie, D.G., AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer. Biochem. Soc. Trans. 39:January (1) (2011), 1–13.
17. [17] Faubert, B., Boily, G., Izreig, S., Griss, T., Samborska, B., Dong, Z., Dupuy, F., Chambers, C., Fuerth, B.J., Viollet, B., Mamer, O.A., Avizonis, D., DeBerardinis, R.J., Siegel, P.M., Jones, R.G., AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 17:January (1) (2013), 113–124.
18. [18] Lim, M.A., Selak, M.A., Xiang, Z., Krainc, D., Neve, R.L., Kraemer, B.C., Watts, J.L., Kalb, R.G., Reduced activity of AMP-activated protein kinase protects against genetic models of motor neuron disease. J. Neurosci. 32:January (3) (2012), 1123–1141.
19. [19] Zhang, C.-X., Pan, S.-N., Meng, R.-S., Peng, C.-Q., Xiong, Z.-J., Chen, B.-L., Chen, G.-Q., Yao, F.-J., Chen, Y.-L., Ma, Y.-D., Dong, Y.-G., Metformin attenuates ventricular hypertrophy by activating the AMP-activated protein kinase-endothelial nitric oxide synthase pathway in rats. Clin. Exp. Pharmacol. Physiol. 38:January (1) (2011), 55–62.
20. [20] Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., Vigneri, R., Diabetes and cancer. Endocr. Relat. Cancer 16:December (4) (2009), 1103–1123.
21. [21] Giovannucci, E., Harlan, D.M., Archer, M.C., Bergenstal, R.M., Gapstur, S.M., Habel, L.A., Pollak, M., Regensteiner, J.G., Yee, D., Diabetes and cancer. Diabetes Care 33:July (7) (2010), 1674–1685.
22. [22] Fransgaard, T., Thygesen, L.C., Gögenur, I., Metformin increases overall survival in patients with diabetes undergoing surgery for colorectal cancer. Ann. Surg. Oncol.(December), 2015, 1–7.
23. [23] Evans, J.M.M., Donnelly, L.A., Emslie-Smith, A.M., Alessi, D.R., Morris, A.D., Metformin and reduced risk of cancer in diabetic patients. BMJ 330:June (7503) (2005), 1304–1305.
24. [24] DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., Gandini, S., Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev. Res. 3:November (11) (2010), 1451–1461.
25. [25] Landman, G.W.D., Kleefstra, N., van Hateren, K.J.J., Groenier, K.H., Gans, R.O.B., Bilo, H.J.G., Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33:February (2) (2010), 322–326.
26. [26] Del Barco, S., Vazquez-Martin, A., Cufí, S., Oliveras-Ferraros, C., Bosch-Barrera, J., Joven, J., Martin-Castillo, B., Menendez, J.A., Metformin: multi-faceted protection against cancer. Oncotarget 2:December (12) (2011), 896–917.
27. [27] Pernicova, I., Korbonits, M., Metformin—mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol., 10(March (3)), 2014, 143156.
28. [28] Minassian, C., Tarpin, S., Mithieux, G., Role of glucose-6 phosphatase, glucokinase, and glucose-6 phosphate in liver insulin resistance and its correction by metformin. Biochem. Pharmacol. 55:April (8) (1998), 1213–1219.
29. [29] Pollak, M., Overcoming drug development bottlenecks With repurposing: repurposing biguanides to target energy metabolism for cancer treatment. Nat. Med. 20:June (6) (2014), 591–593.
30. [30] Febbraro, T., Lengyel, E., Romero, I.L., Old drug, new trick: repurposing metformin for gynecologic cancers?. Gynecol. Oncol. 135:December (3) (2014), 614–621.
31. [31] Kasznicki, J., Sliwinska, A., Drzewoski, J., Metformin in cancer prevention and therapy. Ann. Transl. Med., 2(June (6)), 2014.
32. [32] Morales, D.R., Morris, A.D., Metformin in cancer treatment and prevention. Annu. Rev. Med. 66 (2015), 17–29.
33. [33] Kourelis, T.V., Siegel, R.D., Metformin and cancer: new applications for an old drug. Med. Oncol. 29:June (2) (2012), 1314–1327.
34. [34] Jalving, M., Gietema, J.A., Lefrandt, J.D., de Jong, S., Reyners, A.K.L., Gans, R.O.B., de Vries, E.G.E., Metformin: taking away the candy for cancer?. Eur. J. Cancer 46:September (13) (2010), 2369–2380.
35. [35] Weinberg, S.E., Chandel, N.S., Targeting mitochondria metabolism for cancer therapy. Nat. Chem. Biol. 11:January (1) (2015), 9–15.
36. [36] Chen, W., Wang, S., Tian, T., Bai, J., Hu, Z., Xu, Y., Dong, J., Chen, F., Wang, X., Shen, H., Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur. J. Hum. Genet. 17:December (12) (2009), 1668–1675.
37. [37] Gallagher, E.J., LeRoith, D., Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann. N. Y. Acad. Sci. 1243:December (1) (2011), 54–68.
38. [38] Viollet, B., Foretz, M., Metformine et cancer. Du diabète au cancer: de nouvelles perspectives thérapeutiques pour la metformine: metformin and cancer. From diabetes to cancer: new therapeutic perspectives for metformin. Méd. Maladies Métaboliques 5:February (1) (2011), 29–37.
39. [39] Pineda, C.T., Ramanathan, S., Fon Tacer, K., Weon, J.L., Potts, M.B., Ou, Y.-H., White, M.A., Potts, P.R., Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell 160:February (4) (2015), 715–728.
40. [40] Mohammed, A., Janakiram, N.B., Brewer, M., Ritchie, R.L., Marya, A., Lightfoot, S., Steele, V.E., Rao, C.V., Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Transl. Oncol., 6(December (6)), 2013, 649 IN7.
41. [41] Choi, Y.K., Park, K.-G., Metabolic roles of AMPK and metformin in cancer cells. Mol. Cells 36:October (4) (2013), 279–287.
42. [42] Brown, K.A., Samarajeewa, N.U., Simpson, E.R., Endocrine-related cancers and the role of AMPK. Mol. Cell. Endocrinol. 366:February (2) (2013), 170–179.
43. [43] Icard, P., Kafara, P., Steyaert, J.-M., Schwartz, L., Lincet, H., The metabolic cooperation between cells in solid cancer tumors. Biochim. Biophys. Acta 1846:August (1) (2014), 216–225.
44. [44] Cairns, R.A., Harris, I.S., Mak, T.W., Regulation of cancer cell metabolism. Nat. Rev. Cancer 11:February (2) (2011), 85–95.
45. [45] Wang, Y.Y., Kuhajda, F.P., Li, J., Finch, T.T., Cheng, P., Koh, C., Li, T., Sokoll, L.J., Chan, D.W., Fatty acid synthase as a tumor marker: its extracellular expression in human breast cancer. J. Exp. Ther. Oncol. 4:July (2) (2004), 101–110.
46. [46] Vazquez-Martin, A., Colomer, R., Brunet, J., Lupu, R., Menendez, J.A., Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif. 41:February (1) (2008), 59–85.
47. [47] Lettieri Barbato, D., Vegliante, R., Desideri, E., Ciriolo, M.R., Managing lipid metabolism in proliferating cells: new perspective for metformin usage in cancer therapy. Biochim. Biophys. Acta (BBA): Rev. Cancer 1845:April (2) (2014), 317–324.
48. [48] Loubière, C., Goiran, T., Laurent, K., Djabari, Z., Tanti, J.-F., Bost, F., Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells. Oncotarget(March), 2015.
49. [49] van Veelen, W., Korsse, S.E., van de Laar, L., Peppelenbosch, M.P., The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling. Oncogene 30:May (20) (2011), 2289–2303.
50. [50] Inoki, K., Zhu, T., Guan, K.-L., TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:November (5) (2003), 577–590.
51. [51] Alexander, A., Walker, C.L., The role of LKB1 and AMPK in cellular responses to stress and damage. FEBS Lett. 585:April (7) (2011), 952–957.
52. [52] Sinnett-Smith, J., Kisfalvi, K., Kui, R., Rozengurt, E., Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. Biochem. Biophys. Res. Commun. 430:January (1) (2013), 352–357.
53. [53] Gwinn, D.M., Shackelford, D.B., Egan, D.F., Mihaylova, M.M., Mery, A., Vasquez, D.S., Turk, B.E., Shaw, R.J., AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30:April (2) (2008), 214–226.
54. [54] Kalender, A., Selvaraj, A., Kim, S.Y., Gulati, P., BrÛlé, S., Viollet, B., Kemp, B.E., Bardeesy, N., Dennis, P., Schlager, J.J., Marette, A., Kozma, S.C., Thomas, G., Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 11:May (5) (2010), 390–401.
55. [55] Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., Bost, F., Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 71:July (13) (2011), 4366–4372.
56. [56] Warburg, O., On the origin of cancer cells. Science 123:February (3191) (1956), 309–314.
57. [57] Menendez, J.A., Joven, J., Cufí, S., Corominas-Faja, B., Oliveras-Ferraros, C., Cuyàs, E., Martin-Castillo, B., López-Bonet, E., Alarcón, T., Vazquez-Martin, A., The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. Cell Cycle 12:April (8) (2013), 1166–1179.
58. [58] Puyraimond-Zemmour, D., Vignot, S., Le métabolisme de la cellule tumorale: l'effet Warburg. Oncologie 15:September (9) (2013), 435–440.
59. [59] Jang, M., Kim, S.S., Lee, J., Cancer cell metabolism: implications for therapeutic targets. Exp. Mol. Med., 45(October (10)), 2013, e45.
60. [60] Loureiro, R., Mesquita, K.A., Oliveira, P.J., Vega-Naredo, I., Mitochondria in cancer stem cells: a target for therapy. Recent Pat. Endocr. Metab. Immune Drug Discov. 7:May (2) (2013), 102–114.
61. [61] Chen, X., Qian, Y., Wu, S., The Warburg effect: evolving interpretations of an established concept. Free Radic. Biol. Med. 79 (2015), 253–263.
62. [62] Hardie, D.G., Alessi, D.R., LKB1 and AMPK and the cancer-metabolism link-ten years after. BMC Biol., 11(April (1)), 2013, 36.
63. [63] Menendez, J.A., Vellon, L., Oliveras-Ferraros, C., Cufí, S., Vazquez-Martin, A., mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging. Cell Cycle 10:November (21) (2011), 3658–3677.
64. [64] Salani, B., Rio, A.D., Marini, C., Sambuceti, G., Cordera, R., Maggi, D., Metformin, cancer and glucose metabolism. Endocr. Relat. Cancer 21:December (6) (2014), R461–R471.
65. [65] Levine, A.J., Puzio-Kuter, A.M., The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330:December (6009) (2010), 1340–1344.
66. [66] Shackelford, D.B., Shaw, R.J., The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 9:August (8) (2009), 563–575.
67. [67] Pollak, M., Potential applications for biguanides in oncology. J. Clin. Invest. 123:September (9) (2013), 3693–3700.
68. [68] Hardie, D.G., AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes 62:July (7) (2013), 2164–2172.
69. [69] Feng, Z., Hu, W., de Stanchina, E., Teresky, A.K., Jin, S., Lowe, S., Levine, A.J., The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 67:April (7) (2017), 3043–3053.
70. [70] Fujihara, S., Kato, K., Morishita, A., Iwama, H., Nishioka, T., Chiyo, T., Nishiyama, N., Miyoshi, H., Kobayashi, M., Kobara, H., Mori, H., Okano, K., Suzuki, Y., Masaki, T., Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo. Int. J. Oncol. 46:May (5) (2015), 2172–2180.
71. [71] Vazquez-Martin, A., Oliveras-Ferraros, C., Lopez-Bonet, E., Menendez, J.A., AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor. Cell Cycle 8:November (22) (2009), 3679–3683.
72. [72] Ben Sahra, I., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J.F., Le Marchand-Brustel, Y., Bost, F., The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27:June (25) (2008), 3576–3586.
73. [73] Joe, S.G., Yoon, Y.H., Choi, J.A., Koh, J.-Y., Anti-angiogenic effect of metformin in mouse oxygen-induced retinopathy is mediated by reducing levels of the vascular endothelial growth factor receptor Flk-1. PLoS One, 10(3), 2015, e0119708.
74. [74] Lund, S.S., Tarnow, L., Stehouwer, C.D.A., Schalkwijk, C.G., Teerlink, T., Gram, J., Winther, K., Frandsen, M., Smidt, U.M., Pedersen, O., Parving, H.-H., Vaag, A.A., Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur. J. Endocrinol. 158:May (5) (2008), 631–641.
75. [75] Tadakawa, M., Takeda, T., Li, B., Tsuiji, K., Yaegashi, N., The anti-diabetic drug metformin inhibits vascular endothelial growth factor expression via the mammalian target of rapamycin complex 1/hypoxia-inducible factor-1α signaling pathway in ELT-3 cells. Mol. Cell. Endocrinol. 399:January (2015), 1–8.
76. [76] Wang, J., Li, G., Wang, Y., Tang, S., Sun, X., Feng, X., Li, Y., Bao, G., Li, P., Mao, X., Wang, M., Liu, P., Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis. Oncotarget(November), 2015.
77. [77] Dallaglio, K., Bruno, A., Cantelmo, A.R., Esposito, A.I., Ruggiero, L., Orecchioni, S., Calleri, A., Bertolini, F., Pfeffer, U., Noonan, D.M., Albini, A., Paradoxic effects of metformin on endothelial cells and angiogenesis. Carcinogenesis 35:May (5) (2014), 1055–1066.
78. [78] Phoenix, K.N., Vumbaca, F., Claffey, K.P., Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res. Treat. 113:January (1) (2009), 101–111.
79. [79] Martin, M.J., Hayward, R., Viros, A., Marais, R., Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2:April (4) (2012), 344–355.
80. [80] Takemura, Y., Osuga, Y., Yoshino, O., Hasegawa, A., Hirata, T., Hirota, Y., Nose, E., Morimoto, C., Harada, M., Koga, K., Tajima, T., Yano, T., Taketani, Y., Metformin suppresses interleukin (IL)-1beta-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells. J. Clin. Endocrinol. Metab. 92:August (8) (2007), 3213–3218.
81. [81] Kim, T.H., Suh, D.H., Kim, M.-K., Song, Y.S., Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer. Biomed. Res. Int., 2014, 2014.
82. [82] Yu, H., Pardoll, D., Jove, R., STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9:November (11) (2009), 798–809.
83. [83] Salminen, A., Hyttinen, J.M.T., Kaarniranta, K., AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan. J. Mol. Med. 89:July (7) (2011), 667–676.
84. [84] Eikawa, S., Nishida, M., Mizukami, S., Yamazaki, C., Nakayama, E., Udono, H., Immune-mediated antitumor effect by type 2 diabetes drug, metformin. PNAS 112:February (6) (2015), 1809–1814.
85. [85] Pearce, E.L., Walsh, M.C., Cejas, P.J., Harms, G.M., Shen, H., Wang, L.-S., Jones, R.G., Choi, Y., Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460:July (7251) (2009), 103–107.
86. [86] Memmott, R.M., Mercado, J.R., Maier, C.R., Kawabata, S., Fox, S.D., Dennis, P.A., Metformin prevents tobacco carcinogen—induced lung tumorigenesis. Cancer Prev. Res. (Phila.) 3:September (9) (2010), 1066–1076.
87. [87] Ding, L., Liang, G., Yao, Z., Zhang, J., Liu, R., Chen, H., Zhou, Y., Wu, H., Yang, B., He, Q., Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages. Oncotarget 6:November (34) (2015), 36441–36455.
88. [88] Algire, C., Moiseeva, O., Deschênes-Simard, X., Amrein, L., Petruccelli, L., Birman, E., Viollet, B., Ferbeyre, G., Pollak, M.N., Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev. Res. 5:April (4) (2012), 536–543.
89. [89] Storozhuk, Y., Hopmans, S.N., Sanli, T., Barron, C., Tsiani, E., Cutz, J.-C., Pond, G., Wright, J., Singh, G., Tsakiridis, T., Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br. J. Cancer 108:May (10) (2013), 2021–2032.
90. [90] Vazquez-Martin, A., Oliveras-Ferraros, C., Cufí, S., Martin-Castillo, B., Menendez, J.A., Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like response. Cell Cycle 10:May (9) (2011), 1499–1501.
91. [91] Hirsch, H.A., Iliopoulos, D., Tsichlis, P.N., Struhl, K., Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69:October (19) (2009), 7507–7511.
92. [92] Song, C.W., Lee, H., Dings, R.P.M., Williams, B., Powers, J., Santos, T.D., Choi, B.-H., Park, H.J., Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci. Rep., 2, 2012, 362.
93. [93] Alison, M.R., Lin, W.-R., Lim, S.M.L., Nicholson, L.J., Cancer stem cells: in the line of fire. Cancer Treatment Rev. 38:October (6) (2012), 589–598.
94. [94] Shigdar, S., Li, Y., Bhattacharya, S., O'Connor, M., Pu, C., Lin, J., Wang, T., Xiang, D., Kong, L., Wei, M.Q., Zhu, Y., Zhou, S., Duan, W., Inflammation and cancer stem cells. Cancer Lett. 345:April (2) (2014), 271–278.
95. [95] Meacham, C.E., Morrison, S.J., Tumour heterogeneity and cancer cell plasticity. Nature 501:September (7467) (2013), 328–337.
96. [96] Gupta, P.B., Fillmore, C.M., Jiang, G., Shapira, S.D., Tao, K., Kuperwasser, C., Lander, E.S., Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146:August (4) (2011), 633–644.
97. [97] Iliopoulos, D., Hirsch, H.A., Struhl, K., Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 71:May (9) (2011), 3196–3201.
98. [98] Bao, B., Wang, Z., Ali, S., Ahmad, A., Azmi, A.S., Sarkar, S.H., Banerjee, S., Kong, D., Li, Y., Thakur, S., Sarkar, F.H., Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev. Res. (Phila.) 5:March (3) (2012), 355–364.
99. [99] Shank, J.J., Yang, K., Ghannam, J., Cabrera, L., Johnston, C.J., Reynolds, R.K., Buckanovich, R.J., Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol. Oncol. 127:November (2) (2012), 390–397.
100. [100] Kim, T.I., Chemopreventive drugs: mechanisms via inhibition of cancer stem cells in colorectal cancer. World J. Gastroenterol. 20:April (14) (2014), 3835–3846.
101. [101] Hirsch, H.A., Iliopoulos, D., Struhl, K., Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc. Natl. Acad. Sci. U. S. A. 110:January (3) (2013), 972–977.
102. [102] Vermeulen, L., De Sousa, F., Melo, E., van der Heijden, M., Cameron, K., de Jong, J.H., Borovski, T., Tuynman, J.B., Todaro, M., Merz, C., Rodermond, H., Sprick, M.R., Kemper, K., Richel, D.J., Stassi, G., Medema, J.P., Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12:May (5) (2010), 468–476.
103. [103] Schwitalla, S., Fingerle, A.A., Cammareri, P., Nebelsiek, T., Göktuna, S.I., Ziegler, P.K., Canli, O., Heijmans, J., Huels, D.J., Moreaux, G., Rupec, R.A., Gerhard, M., Schmid, R., Barker, N., Clevers, H., Lang, R., Neumann, J., Kirchner, T., Taketo, M.M., van den Brink, G.R., Sansom, O.J., Arkan, M.C., Greten, F.R., Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 2:January (2013), 25–38.
104. [104] Janzer, A., German, N.J., Gonzalez-Herrera, K.N., Asara, J.M., Haigis, M.C., Struhl, K., Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc. Natl. Acad. Sci. U. S. A. 111:July (29) (2014), 10574–10579.
105. [105] Huang, N.-L., Chiang, S.-H., Hsueh, C.-H., Liang, Y.-J., Chen, Y.-J., Lai, L.-P., Metformin inhibits TNF-α-induced IκB kinase phosphorylation, IκB-α degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. Int. J. Cardiol. 134:May (2) (2009), 169–175.
106. [106] Iliopoulos, D., Hirsch, H.A., Wang, G., Struhl, K., Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. PNAS 108:January (4) (2011), 1397–1402.
107. [107] Feliciano, P., Metformin in cancer. Nat. Genet., 45(February (2)), 2013 123–123.
108. [108] Huang, J., Nguyen-McCarty, M., Hexner, E.O., Danet-Desnoyers, G., Klein, P.S., Maintenance of hematopoietic stem cells through regulation of Wnt and mTOR pathways. Nat. Med. 18:December (12) (2012), 1778–1785.
109. [109] Kalluri, R., Weinberg, R.A., The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119:June (6) (2009), 1420–1428.
110. [110] Yang, G., Quan, Y., Wang, W., Fu, Q., Wu, J., Mei, T., Li, J., Tang, Y., Luo, C., Ouyang, Q., Chen, S., Wu, L., Hei, T.K., Wang, Y., Dynamic equilibrium between cancer stem cells and non-stem cancer cells in human SW620 and MCF-7 cancer cell populations. Br. J. Cancer 106:April (9) (2012), 1512–1519.
111. [111] Zhang, R., Zhang, P., Wang, H., Hou, D., Li, W., Xiao, G., Li, C., Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells. Stem Cell Res. Ther., 6(1), 2015, 262.
112. [112] Boyerinas, B., Park, S.-M., Hau, A., Murmann, A.E., Peter, M.E., The role of let-7 in cell differentiation and cancer. Endocr. Relat. Cancer 17:March (1) (2010), F19–36.
113. [113] Oliveras-Ferraros, C., Cufí, S., Vazquez-Martin, A., Torres-Garcia, V.Z., Del Barco, S., Martin-Castillo, B., Menendez, J.A., Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a. Cell Cycle 10:April (7) (2011), 1144–1151.
114. [114] Zhang, J., Nuebel, E., Daley, G.Q., Koehler, C.M., Teitell, M.A., Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal. Cell Stem Cell 11:November (5) (2012), 589–595.
115. [115] Lamb, R., Ozsvari, B., Lisanti, C.L., Tanowitz, H.B., Howell, A., Martinez-Outschoorn, U.E., Sotgia, F., Lisanti, M.P., Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease. Oncotarget 6:January (7) (2015), 4569–4584.
116. [116] Lonardo, E., Cioffi, M., Sancho, P., Sanchez-Ripoll, Y., Trabulo, S.M., Dorado, J., Balic, A., Hidalgo, M., Heeschen, C., Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS One, 8(10), 2013, e76518.
117. [117] Pastò, A., Bellio, C., Pilotto, G., Ciminale, V., Silic-Benussi, M., Guzzo, G., Rasola, A., Frasson, C., Nardo, G., Zulato, E., Nicoletto, M.O., Manicone, M., Indraccolo, S., Amadori, A., Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. Oncotarget 5:May (12) (2014), 4305–4319.
118. [118] Mayer, M.J., Klotz, L.H., Venkateswaran, V., Metformin and prostate cancer stem cells: a novel therapeutic target. Prostate Cancer Prostatic Dis. 18:December (4) (2015), 303–309.
119. [119] Vazquez-Martin, A., Vellon, L., Quirós, P.M., Cufí, S., Ruiz de Galarreta, E., Oliveras-Ferraros, C., Martin, A.G., Martin-Castillo, B., López-Otín, C., Menendez, J.A., Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells. Cell Cycle 11:March (5) (2012), 974–989.
120. [120] Folmes, C.D.L., Nelson, T.J., Terzic, A., Energy metabolism in nuclear reprogramming. Biomark Med. 5:December (6) (2011), 715–729.
121. [121] Liu, W., Monahan, K.B., Pfefferle, A.D., Shimamura, T., Sorrentino, J., Chan, K.T., Roadcap, D.W., Ollila, D.W., Thomas, N.E., Castrillon, D.H., Miller, C.R., Perou, C.M., Wong, K.-K., Bear, J.E., Sharpless, N.E., LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 21:June (6) (2012), 751–764.
122. [122] Ji, H., Ramsey, M.R., Hayes, D.N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M.C., Shimamura, T., Perera, S.A., Liang, M.-C., Cai, D., Naumov, G.N., Bao, L., Contreras, C.M., Li, D., Chen, L., Krishnamurthy, J., Koivunen, J., Chirieac, L.R., Padera, R.F., Bronson, R.T., Lindeman, N.I., Christiani, D.C., Lin, X., Shapiro, G.I., Jänne, P.A., Johnson, B.E., Meyerson, M., Kwiatkowski, D.J., Castrillon, D.H., Bardeesy, N., Sharpless, N.E., Wong, K.-K., LKB1 modulates lung cancer differentiation and metastasis. Nature 448:August (7155) (2007), 807–810.
123. [123] Wingo, S.N., Gallardo, T.D., Akbay, E.A., Liang, M.-C., Contreras, C.M., Boren, T., Shimamura, T., Miller, D.S., Sharpless, N.E., Bardeesy, N., Kwiatkowski, D.J., Schorge, J.O., Wong, K.-K., Castrillon, D.H., Somatic LKB1 mutations promote cervical cancer progression. PLoS One, 4(4), 2009, e5137.
124. [124] Su, G.H., Hruban, R.H., Bansal, R.K., Bova, G.S., Tang, D.J., Shekher, M.C., Westerman, A.M., Entius, M.M., Goggins, M., Yeo, C.J., Kern, S.E., Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am. J. Pathol. 154:June (6) (1999), 1835–1840.
125. [125] Menendez, J.A., Oliveras-Ferraros, C., Cufí, S., Corominas-Faja, B., Joven, J., Martin-Castillo, B., Vazquez-Martin, A., Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle 11:August (15) (2012), 2782–2792.
126. [126] Pollak, M.N., Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2:September (9) (2012), 778–790.
127. [127] Buzzai, M., Jones, R.G., Amaravadi, R.K., Lum, J.J., DeBerardinis, R.J., Zhao, F., Viollet, B., Thompson, C.B., Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67:July (14) (2007), 6745–6752.
128. [128] Duffy, M.J., Synnott, N.C., McGowan, P.M., Crown, J., O'Connor, D., Gallagher, W.M., p53 as a target for the treatment of cancer. Cancer Treat. Rev. 40:December (10) (2014), 1153–1160.
129. [129] Nies, A.T., Hofmann, U., Resch, C., Schaeffeler, E., Rius, M., Schwab, M., Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS One, 6(7), 2011, e22163.
130. [130] Andrzejewski, S., Gravel, S.-P., Pollak, M., St-Pierre, J., Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab., 2(August), 2014, 12.
131. [131] Shu, Y., Sheardown, S.A., Brown, C., Owen, R.P., Zhang, S., Castro, R.A., Ianculescu, A.G., Yue, L., Lo, J.C., Burchard, E.G., Brett, C.M., Giacomini, K.M., Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117:May (5) (2007), 1422–1431.
132. [132] Song, I.-S., Han, J., Lee, H.K., Metformin as an anticancer drug: a commentary on the metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. J. Diabetes Invest.(December), 2014 p. n/a-n/a.
133. [133] Birsoy, K., Possemato, R., Lorbeer, F.K., Bayraktar, E.C., Thiru, P., Yucel, B., Wang, T., Chen, W.W., Clish, C.B., Sabatini, D.M., Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature(March), 2014 vol. advance online publication.
134. [134] Wang, Z., Lai, S.-T., Ma, N.-Y., Deng, Y., Liu, Y., Wei, D.-P., Zhao, J.-D., Jiang, G.-L., Radiosensitization of metformin in pancreatic cancer cells via abrogating the G2 checkpoint and inhibiting DNA damage repair. Cancer Lett. 369:December (1) (2015), 192–201.
135. [135] Koritzinsky, M., Metformin: a novel biological modifier of tumor response to radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 93:October (2) (2015), 454–464.
136. [136] Vander Heiden, M.G., Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 10:September (9) (2011), 671–684.
137. [137] Search of: metformin and cancer − List Results − ClinicalTrials.gov. [Online]. Available: https://clinicaltrials.gov/ct2/results?term=metformin +and+cancer&Search=Search. (accessed 27.06.15.).
138. [138] Kordes, S., Pollak, M.N., Zwinderman, A.H., Mathôt, R.A., Weterman, M.J., Beeker, A., Punt, C.J., Richel, D.J., Wilmink, J.W., Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol.(June), 2015.
139. [139] Singh, P.P., Shi, Q., Foster, N.R., Grothey, A., Nair, S., Chan, E., Shields, A.F., Goldberg, R.M., Gill, S., Kahlenberg, M.S., Sinicrope, F.A., Sargent, D.J., Alberts, S.R., Relationship between metformin use and recurrence and survival in patients (pts) with resected stage III colon cancer (CC) receiving adjuvant chemotherapy: results from NCCTG N0147 (Alliance). ASCO Meet. Abstr., 33(May (15)_suppl), 2015, 3531.
140. [140] Pryor, R., Cabreiro, F., Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem. J. 471:November (3) (2015), 307–322.
141. [141] Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group, Lancet, vol. 352, no. 9131, pp. 854–865, Sep. 1998.